Evidence map›Paper›PMID 35099487›Full record

ReviewChemical Society reviews2022

Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future.

Sajal Sen, Miae Won, Matthew S Levine, Yuvin Noh, Adam C Sedgwick, Jong Seung Kim, Jonathan L Sessler, Jonathan F Arambula

Open access · greenAbstract readReview
In one paragraph

Review in Chemical Society reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
24.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 254 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. A Catalytic Osmium Redox Couple Collapses Cancer Redox Balance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Carrier-free GSH-responsiveMaterials today. Bio · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Viral mimicry may help explain immunogenic cell death.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  17. Article
  18. Review
  19. Review
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Sajal SenDepartment of Chemistry, The University of Texas at Austin, Austin, Texas 78712-1224, USA. sessler@cm.utexas.edu.ORCID http://orcid.org/0000-0002-1189-4156
Miae WonDepartment of Chemistry, Korea University, Seoul 02841, Korea. jongskim@korea.ac.kr.ORCID http://orcid.org/0000-0002-1656-6362
Matthew S LevineDepartment of Chemistry, The University of Texas at Austin, Austin, Texas 78712-1224, USA. sessler@cm.utexas.edu.
Yuvin NohDepartment of Chemistry, Korea University, Seoul 02841, Korea. jongskim@korea.ac.kr.
Adam C SedgwickDepartment of Chemistry, The University of Texas at Austin, Austin, Texas 78712-1224, USA. sessler@cm.utexas.edu.ORCID http://orcid.org/0000-0002-3132-2913
Jong Seung KimDepartment of Chemistry, Korea University, Seoul 02841, Korea. jongskim@korea.ac.kr.ORCID http://orcid.org/0000-0003-3477-1172
Jonathan L SesslerDepartment of Chemistry, The University of Texas at Austin, Austin, Texas 78712-1224, USA. sessler@cm.utexas.edu.ORCID http://orcid.org/0000-0002-9576-1325
Jonathan F ArambulaDepartment of Chemistry, The University of Texas at Austin, Austin, Texas 78712-1224, USA. sessler@cm.utexas.edu.ORCID http://orcid.org/0000-0003-2342-8440
The University of Texas at Austin · USKorea University · KR

Funding

Biomedical Applications of Expanded Porphyrins: Development of Gold-Texaphyrin ConjugatesR01CA068682 · NCI · UNIVERSITY OF TEXAS AUSTIN · PI Esther Y. Maier, Emily L Que · 1995 to 2026
$7.4M
Dual Targeting Redox‐active Gold(I) TherapeuticsR15CA232765 · NCI · WRIGHT STATE UNIVERSITY · PI ARUMUGAM, KUPPUSWAMY · 2018 to 2018
$462k
NCI NIH HHS R01 CA068682NCI NIH HHS R15 CA232765
6 · The paper itself

Abstract

Cancer is the deadliest disease in the world behind heart disease. Sadly, this remains true even as we suffer the ravages of the Covid-19 pandemic. Whilst current chemo- and radiotherapeutic treatment strategies have significantly improved the patient survival rate, disease reoccurrence continues to pose a deadly risk for all too many patients. Incomplete removal of tumour cells from the body increases the chances of metastasis and developing resistance against current treatments. Immunotherapy represents a therapeutic modality that has helped to overcome these limitations in recent decades. However, further progress is needed. So-called immunogenic cell death (ICD) is a recently discovered and unique mode of cell death that could trigger this necessary further progress. ICD involves stimulation of a tumour-specific immune response as a downstream effect. Facilitated by certain treatment modalities, cells undergoing ICD can trigger the IFN-γ mediated immune response involving cytotoxic T cells (CTLs) and γδ T cells that eradicate residual tumour cells. In recent years, there has been a significant increase in the number of small-molecules being tested as potential ICD inducers. A large number of these ICD inducers are metal-based complexes. In fact, anticancer metal drugs based on Pt, Ru, Ir, Cu, and Au are now known to give rise to an immune response against tumour cells as the result of ICD. Advances have also been made in terms of exploiting combinatorial and delivery strategies. In favourable cases, these approaches have been shown to increase the efficacy of otherwise ICD "silent" metal complexes. Taken in concert, rationally designed novel anticancer metal complexes that can act as ICD inducers show promise as potential new immunotherapies for neoplastic disease. This Tutorial Review will allow the readers to assess the progress in this fast-evolving field thus setting the stage for future advances.

Indexed as

Antineoplastic AgentsCOVID-19NeoplasmsHumansImmunogenic Cell DeathImmunotherapyPandemicsSARS-CoV-2Antineoplastic Agents

Identifiers

PMID35099487
PMCPMC9398513
OpenAlexW4210763359

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.